# Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

> **NCT02052739** · PHASE1,PHASE2 · COMPLETED · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Super-refractory Status Epilepticus

## Interventions

- **DRUG:** SAGE-547

## Key facts

- **NCT ID:** NCT02052739
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-21
- **Primary completion:** 2015-05-03
- **Final completion:** 2015-05-03
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02052739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02052739, "Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT02052739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*